Expect midcap pharma stocks to perform well in 2016: Deepak Shenoy.

In a chat with ET Now, Deepak Shenoy, Founder, Capital Mind, shares his top sectoral bet for 2016.

ET Now: Share with us one big idea for 2016?
Deepak Shenoy: I do not have a single theme that may play out in 2016, but I still believe that it is going to be midcap pharma stocks.
ET Now: Is there any midcap pharma name which particularly stands out?
Deepak Shenoy: I am as biased as any investor. I do like Strides Shasun a lot. But many smaller players have starting to look really good. From Torrent to Dishman Pharma, many pharma stocks are ruling at slightly lower PEs than Strides; they have strong growth prospects and are not finding much attention from the USFDA as some of the bigger players have. We believe these stocks will outperform in the next year. Large cap pharma stocks may though take some time to recover.